| Literature DB >> 21929782 |
Jia V Li1, Jasmina Saric, Yulan Wang, Jennifer Keiser, Jürg Utzinger, Elaine Holmes.
Abstract
BACKGROUND: The urinary metabolic fingerprint of a patent Schistosoma mansoni infection in the mouse has been characterized using spectroscopic methods. However, the temporal dynamics of metabolic alterations have not been studied at the systems level. Here, we investigated the systems metabolic changes in the mouse upon S. mansoni infection by modeling the sequence of metabolic events in urine, plasma and faecal water.Entities:
Mesh:
Year: 2011 PMID: 21929782 PMCID: PMC3183007 DOI: 10.1186/1756-3305-4-179
Source DB: PubMed Journal: Parasit Vectors ISSN: 1756-3305 Impact factor: 3.876
Figure 1Graph showing packed cell volume (PCV) ratio of uninfected control and . The graph shows a significant decrease in PCV of infected mice from day 48 post-infection onwards. The error bars represent 2x standard deviation.
Figure 2Typical 600 MHz . A 3-D PCA trajectory scores plot (C) derived from urinary spectra of both control (black), S. mansoni-infected mice at early stage (13-41 days post-infection, blue) and these infected mice at the late stage (48-73 days post-infection, red). D and E represent 2-D PCA scores plots constructed from first and second PCs (D), and first and third PCs (E), respectively.
Identified metabolites in 1H NMR spectra of urine (u), plasma (p) and faecal water (f) obtained from mice with or without an infection of S.mansoni, together with the respective chemical shifts and signal multiplicities
| No | Metabolites | H group | δ 1H (multiplicity*) | Biofluids |
|---|---|---|---|---|
| 1 | 2-oxoadipate | β-CH2; γ-CH2; δ-CH2 | 2.77(t); 1.82(m); 2.22(t) | u |
| 2 | 2-oxoglutarate | β-CH2; γ-CH2 | 3.01(t); 2.45(t) | u |
| 3 | 2-oxoisocaproate | β-CH2; γ-CH; 2x CH3 | 2.61(d); 2.1(m); 0.94(d) | u |
| 4 | 2-oxoisovalerate | β-CH; 2x CH3 | 3.02(m); 1.13(d) | u/f |
| 5 | 3-carboxy-2-methyl-3-oxopropanamine | β-CH; CH3; γ-CH2 | 2.49(m); 1.08(d); 3.19(m), 3.56(m), 3.72(m) | u |
| 6 | 3-methyl-2-oxovalerate | β-CH; β-CH3; γ-CH2(i); γ-CH2(ii); γ-CH3 | 2.93(m); 1.1(d); 1.7(m); 1.46(m); 0.9(t) | u/f |
| 7 | 3-ureidopropionic acid | α-CH2; β-CH2 | 2.38(t); 3.31(t) | u |
| 8 | 5-aminovalerate | α-CH2; β-CH2; γ-CH2; δ-CH2 | 2.24(t); 1.64(m); 1.66(m); 3.02(t) | f |
| 9 | acetate | CH3 | 1.93(s) | u/p/f |
| 10 | alanine | CH; CH3 | 3.77(q); 1.47(d) | p/f |
| 11 | arginine | α-CH; β-CH2; γ-CH2; δ-CH2 | 3.78(t); 1.92(m); 1.65(m); 3.20(t) | u/f |
| 12 | asparagine | α-CH; β-CH2 | 4.01(dd); 2.87(dd),2.95(dd) | f |
| 13 | aspartate | α-CH; β-CH2 | 3.89(dd); 2.69(dd),2.80(dd) | f |
| 14 | butyrate | α-CH2; β-CH2; CH3 | 2.16(t); 1.56(m); 0.9(t) | f |
| 15 | choline | 3.20(s); 4.07(m); 3.52(m) | p/f | |
| 16 | citrate | CH2(i); CH2(ii) | 2.66(d); 2.54(d) | u/p |
| 17 | creatine | 3.03(s); 3.92(s) | u/p | |
| 18 | creatinine | 3.03(s); 4.05(s) | u | |
| 19 | cytidine | 5-CH; 6-CH | 6.10(d); 7.85(d) | f |
| 20 | cytosine | 5-CH; 6-CH | 5.98(d); 7.51(d) | f |
| 21 | D-3-hydroxybutyrate | α-CH2(i); α-CH2(ii); β-CH; CH3 | 2.41(dd); 2.31(dd); 4.16(m); 1.2(d) | p |
| 22 | Dimethylamine | 2x CH3 | 2.72(s) | u |
| 23 | Glutamate | α-CH; β-CH2; γ-CH2 | 3.76(t); 2.07(m); 2.34(m) | f |
| 24 | Glutamine | α-CH; β-CH2; γ-CH2 | 3.78(t); 2.12(m); 2.43(m) | p/f |
| 25 | glycerophosphorylcholine | 3.22(s); 4.32(t); 3.68(t); 3.61(dd); 3.90(m); 3.72(dd) | p | |
| 26 | glyceryl of lipids | C | 4.28(m) | p |
| 27 | Glycine | CH | 3.55(s) | f |
| 28 | Hippurate | CH2; 2,6-CH; 3,5-CH; 4-CH | 3.97(d); 7.84(d); 7.55(t); 7.64 (t) | u |
| 29 | Isoleucine | α-CH; β-CH; β-CH3; γ-CH2 (i); γ-CH2(ii); CH3 | 3.68(d); 1.98(m); 1.02(d);1.25(m),1.47(m); 0.94(t) | p/f |
| 30 | Lactate | α-CH; β-CH3 | 4.11(q);1.32(d) | u/p/f |
| 31 | Leucine | α-CH; β-CH2; γ-CH; 2x CH3 | 3.72(t); 1.74(m), 1.70(m); 0.96(t) | p/f |
| 32 | lipid fraction | C | 2.0(bs) | p |
| 33 | lipid fraction | C | 2.22(bs) | p |
| 34 | lipid fraction | C = CC | 2.75(bs) | p |
| 35 | lipid fraction | C | 5.30(bs) | p |
| 36 | lipid fraction | C | 0.83(bs) | p |
| 37 | lipid fraction | (C | 1.22(bs) | p |
| 38 | lipid fraction | C | 0.87(bs) | p |
| 39 | lipid fraction | C | 1.57(bs) | p |
| 40 | Lysine | α-CH; β-CH2; γ-CH2; δ-CH2; ε-CH2 | 3.78(t); 1.92(m); 1.72(m); 1.47(m); 3.03(t) | u/p/f |
| 41 | Methionine | α-CH; β-CH2; γ-CH2; | 3.87(t); 2.14(m); 2.63(t); 2.13(s) | f |
| 42 | NHCOC | 2.06(s) | u/f | |
| 43 | Nicotinurate | 2-CH; 6-CH; 4-CH; 5-CH; CH2 | 8.92(s); 8.70(d); 8.24(d); 7.60(dd); 3.99(s) | f |
| 44 | 2,6-CH; 3,5-CH; CH3 | 7.06(d); 7.23(d); 2.3(s) | u | |
| 45 | Phenylacetylglycine | 3,5-CH; 2,4,6-CH; Ar-CH2; | 7.43 (m); 7.37 (m); 3.75 (d); 3.68 (s) | u |
| 46 | Phenylalanine | 2,6-CH; 3,5-CH; 4-CH; half Ar-CH2; half Ar-CH2; | 7.33(d); 7.43(m); 7.36(m); 3.17(dd),3.30(dd); 3.99(dd) | f |
| 47 | Proline | α-CH; half β-CH2; half β-CH2; γ-CH2; δ-CH2 | 4.13(dd); 2.08(m), 2.37(m); 2.01(m); 3.38(m) | f |
| 48 | Propionate | CH2; CH3 | 2.19(m); 1.06(t) | f |
| 49 | Pyruvate | CH3 | 2.36(s) | u/p |
| 50 | 6x CH | 3.33(s) | u/f | |
| 51 | Succinate | 2x CH2 | 2.41(s) | u/f |
| 52 | Taurine | 3.43(t); 3.27(t) | u/f | |
| 53 | Threonine | α-CH; β-CH; CH3 | 3.59(d); 4.27(m); 1.32(d) | f |
| 54 | Trimethylamine | 3x CH3 | 2.89(s) | u/f |
| 55 | trimethylamine | 3x CH3 | 3.28(s) | u |
| 56 | Tyrosine | 2,6-CH; 3,5-CH; α-CH; β-CH2 | 7.18(d); 6.88(d); 3.94(dd); 3.20(dd), 3.10(dd) | f |
| 57 | UN | 4.11(bs); 3.75(m); 3.65(m) | p | |
| 58 | Uracil | 5-CH; 6-CH | 5.80(d); 7.52(d) | f |
| 59 | Valine | α-CH; β-CH; γ-CH3; γ'-CH3 | 3.62(d); 2.28(m); 0.99(d); 1.04(d) | p/f |
| 60 | α-glucose | 1-H; 2-H; 3-H; 4-H; 5-H; CH2(i); CH2(ii) | 5.22(d); 3.54(dd); 3.71(t); 3.42(t); 3.83(ddd); 3.84(m); 3.76(m) | p/f |
| 61 | β-glucose | 1-H; 2-H; 3-H; 4-H; 5-H; CH2(i); CH2(ii) | 4.65(d); 3.24(dd); 3.48(t); 3.40(t); 3.47(ddd); 3.72(dd); 3.90(dd) | p/f |
*s, singlet; d, doublet; t, triplet; m, multiplet; q, quadruplet; dd, double doublet; ddd, double double doublet; bs, broad signal.
Figure 3O-PLS-DA coefficient plots derived from .
Figure 4Summary of . Colour keys are as follows: yellow, urine; red, plasma; blue, faecal water. Stability of metabolites, as candidate biomarkers of infection, is indicated by dark green through white corresponding to a progressive decrease in stability. Increasing stability of metabolites refers to the constancy of the metabolite as a significant biomarker for the discrimination of the infected mice from the controls during the entire course of the experiment. Numerical values are the coefficient covariance values for each metabolite and for plasma metabolites, 'A/B' format represents that value A is from models based on 1H standard plasma spectra, while value B is from models obtained from CPMG spectra. NA represents no significant correlation observed.
Figure 5Typical 1-D . PCA scores plots derived from 1H standard (C) and CPMG (D) NMR spectral data (black, control; blue, S. mansoni-infected mice at the early stage of the infection (≤ 41 days); red, these mice at later stage of the infection (≥ 48 days)).
Figure 6O-PLS-DA coefficient plots derived from plasma spectral data acquired using standard (A), CPMG (B) and diffusion-edited (C) pulse sequences on 53 days post-infection showing discriminatory metabolites for infection.
Figure 7Typical . O-PLS-DA coefficient plots derived from 1H NMR faecal extract spectra at day 61 (C) and 73 (D) (Q2Y = 0.86 and 0.83, R2X = 49% and 66% of the total variance, respectively), reflecting the discrimination between the S. mansoni-infected and uninfected control mice.
Figure 8Schematic illustration of correlations between faecal metabolites (e.g. propionate, aspartate, 5-aminovalerate, . A solid line represents positive correlation between two metabolites, whilst a dashed line represents negative correlation. Dx indicates the data points at which the correlation was observed.
Figure 9Schematic illustration of systematic changes observed in biofluids from [14]). Key: TCA, tricarboxylic acid.